ArticleDEN open2026
Potassium-Competitive Acid Blocker-Associated Gastric Hyperplastic Polyps With Severe Bleeding: A Case Series.
Article in DEN open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between Gastric Acid Suppression Therapy and Scattered White Spots in the Duodenum: A Retrospective Observational Study.Endoscopy international open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric hyperplastic polyps can cause gastrointestinal bleeding, and their enlargement has been associated with long-term acid-suppressive therapy. Vonoprazan (VPZ), a potassium-competitive acid blocker, provides potent acid suppression and may induce hypergastrinemia, potentially contributing to the growth of hyperplastic polyps. However, clinical information regarding VPZ-associated gastric hyperplastic polyps remains limited. We report three cases of severe bleeding from gastric hyperplastic polyps in patients who were administered VPZ. Case 1 involved a 92-year-old woman who presented with melena and anemia. Endoscopy revealed an 8-cm hyperplastic polyp, and although resection was considered, it was deferred. After switching from VPZ to an H2-receptor antagonist (H2RA), her anemia gradually improved, and the polyp regressed. Case 2 involved a 61-year-old man with hematemesis due to bleeding from multiple hyperplastic polyps. Emergency endoscopic mucosal resection was performed, and markedly elevated serum gastrin levels were noted. Following the replacement of VPZ with an H2RA, the size of the remaining polyps decreased. Case 3 involved a 54-year-old man with anemia and recurrent bleeding from hyperplastic polyps, requiring multiple endoscopic treatments. After VPZ discontinuation and H2RA initiation, the unresected polyps regressed. Two patients were undergoing hemodialysis, which may have exacerbated hypergastrinemia and bleeding. In all three cases, switching from VPZ to an H2RA resulted in the regression of gastric hyperplastic polyps and improvement of anemia. In patients receiving VPZ who develop progressive anemia or bleeding from hyperplastic polyps, discontinuation of VPZ or switching to an H2RA may be effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.